Jennifer R. Cochran's Insider Trades & SAST Disclosures
Jennifer R. Cochran's most recent trade in OmniAb Inc was a trade of 30,000 Common Stock done at an average price of $1.5 . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jennifer R. Cochran.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OmniAb Inc | Jennifer R. Cochran | Director | Purchase of securities on an exchange or from another person at price $ 1.52 per share. | 15 May 2025 | 30,000 | 145,274 | - | 1.5 | 45,600 | Common Stock |
| OmniAb Inc | Jennifer R. Cochran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 1,896 | 115,274 | - | - | Common Stock | |
| OmniAb Inc | Jennifer R. Cochran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 1,896 | 20,000 | - | - | Restricted Stock Units | |
| OmniAb Inc | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | Jennifer R. Cochran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 1,896 | - | - | Restricted Stock Units | |
| OmniAb Inc | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 21,896 | - | - | Restricted Stock Units | |
| OmniAb Inc | Jennifer R. Cochran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 113,378 | - | - | Common Stock | |
| OmniAb Inc | Jennifer R. Cochran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2023 | 1,896 | 21,896 | - | - | Restricted Stock Units | |
| OmniAb Inc | Jennifer R. Cochran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2023 | 1,896 | 93,086 | - | - | Common Stock | |
| OmniAb Inc | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 25,518 | 93,378 | - | - | Common Stock | |
| Ligand Pharmaceuticals, In... | Jennifer R. Cochran | Former Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 4,340 | 0 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Jennifer R. Cochran | Former Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Nov 2022 | 1,004 | 1,161 (0%) | 0% | - | Common Stock | |
| Ligand Pharmaceuticals, In... | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 2,165 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2021 | 4,508 | 4,508 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Jennifer R. Cochran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2021 | 1,161 | 1,161 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges